TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of patients included in clinical trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Days Used Drugs or Alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety after intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Cranio vertebral angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Pregnancies and Pregnancy Outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the concentrations of plasma lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in the intake of nutrients and nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of asthma-related hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: FEV1 (Forced Expiratory Volume in 1 sec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline of drowsiness on Stanford Sleepiness Scale 1 hour after administration of diphenhydramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of drowsiness on Stanford Sleepiness Scale upon arrival at home
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of drowsiness on Stanford Sleepiness Scale the morning after administration of diphenhydramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-168 (Area Under the Concentration-time Curve of Clonidine in Plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cavg (Average of Measured Concentrations of Clonidine in Plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to EEG normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety as measured by clinical laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as measured by ECG/holter monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety as measured by echocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Glucagon-Stimulated C-Peptide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incision Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Percent Correct of Trained Scripts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Words Per Minute of Trained Scripts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color vision assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Individuals Randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in SAS BARS AIMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea and Vomiting in Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary distress inventory (UDI) overall score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean cancer stress scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Natural Killer (NK) cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain level estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Tolerability Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: white spot lesion progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days breathing without assistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Relapsed Leukemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Success of implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prothetic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Opinion of the patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients Undergoing Complete Unsedated Colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants With Clinical Response (CR) to Tigecycline at Last Day of Therapy (LDOT) and Test-of-Cure (TOC) Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight of food served and left-overs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection rate of GIN and EGC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WHODAS 2.0 Response Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacokinetic profile (AUC, Cmax, Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in aggressive behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Survival in ALS-Patients
Endpoint domain: Mortality/survival
Primary endpoint: Change of psychoactive substances concentration in newborn's hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Rotavin-M1 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Lumbar Spine Bone Mineral Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of microbiologically documented infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of iatrogenic pneumothorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for intervention with EPABI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subjective satiety evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Summed pain intensity score (SPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Loss of dopaminergic neurons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Pre-dose FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HES4 gene expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic impact of outpatient ECG telemetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax of study drugs after single oral administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of study drugs after single oral administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic response to bulevirtide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: follicular fluid metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of infectious disease episodes
Endpoint domain: Adverse events/effects
Primary endpoint: M3G concentration in blood over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: M6G concentration in blood over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Noroxycodone concentration in blood over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oxymorphone concentration in blood over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: VX 770 pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bimanual coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time In Range (TIR) 3.5-7.8 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrosis measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contracture Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean Change in Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Prothrombin Fragment 1 and 2 (PF 1.2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasmin-a 2 Antiplasmin Complex (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Epicardial Adipose Tissue (EAT) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Requiring 2nd Surgery for Close or Positive Margins
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical attack rate for viral gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and acute toxicity monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Human infectious dose 50 percent based on viral shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain-related interference with functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FEV1-time curve (day 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1-time curve (day 28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum/Urine Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled Carbon Monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration change of ubiquinol and ubiquinone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reduction in malaria incidence
Endpoint domain: Mortality/survival
Primary endpoint: Sustained Viral Response (SVR 12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Retention to GTP
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Amount of tin in GCF sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent with postprandial glucose level in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite of clinical cerebral infarct or new cerebral MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient reported experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: arterial vascular stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Interval between drug use to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants reporting immediate adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants reporting serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean concentrations (GMCs) of anti-pertussis antigen immunoglobulins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Grams of vegetables consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Opioid Use Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indwelling time of Peripheral Intravenous Cannula (PIVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (complications related to PIVC)
Endpoint domain: Adverse events/effects
Primary endpoint: Change on Visual Acuity (VA) of the Treated Eyes From Baseline to the End of the Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Number of Letters Seen on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Eyes That Improved VA From Baseline to End of the Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Drug Therapy Problems (DTPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of long term complications
Endpoint domain: Adverse events/effects
Primary endpoint: FEV1 Standardized Area Under the Curve (AUC 0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CCQ-recovery time in the event of an exacerbation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early hypothyroidism after RAI therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in the prevalence of musculoskeletal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in the intensity of musculoskeletal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in median pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS-Rated Tinnitus Loudness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammation associated with ferrous iron supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: lipid peroxidation associated with ferrous iron supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: acute iron absorption associated with ferrous iron supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: iron status associated with ferrous iron supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of debonded crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in VAS-A Rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PLMS-arousal index (PLMS-AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Shoulder Elbow Society Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient remission status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ambulatory Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Strength (Knee Flexion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Strength (Knee Extension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensitivity of WLE, NBI and ISE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Specificity of WLE, NBI and ISE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Positive predictive value (PPV) of WLE, NBI and ISE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Negative predictive value (NPV) of WLE, NBI and ISE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Protein to creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: SN^GoGn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain and function as measured by WOMAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's global rating of change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Trunk Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients who experienced one or more adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in level of distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence rate of HBV reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Symlin in type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of Symlin in type 2 diabetes
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Von Korff Pain Scale for low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Von Korff Disability Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients whose tumors transformed from a class 2 phenotype into a cell phenotype that resembles normal melanocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemagglutination Inhibition (HI) Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of Subjects Achieving Seroconversion (SC) in Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dynamic range of Total Blood Flow biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic range of Arterial Blood Flow Fraction biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic range of Extracellular Volume biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic range of Intracellular Uptake Rate biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic range of Biliary Excretion Rate biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol Use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: In-hospital Postoperative Morbidity and Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Sensibility and specificity of dry swabs for HPV diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial Length of the Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intermetatarsal 1-2 angle postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of acute renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety evaluation indicators
Endpoint domain: Adverse events/effects
Primary endpoint: DOB Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of USADEs and ASADEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Myeloid Mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recurrence of thromboembolisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction of Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dosage of biomarkers in ICU delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dosage of neuronal injury markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Body Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parental Bonding
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Physical subscale score of the MSIS-29v1
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in fecal concentration of LGG and BB-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of ≥3 grade TRAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Gugging swallowing screen test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4
Endpoint domain: Mortality/survival
Primary endpoint: Subject's degree of response at 2-4 weeks post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (AE) including serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: The degree of pain during treatment
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Isolation of a plasma cell clone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of POCD or delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes